CYAD Celyad Oncology

Celyad Oncology SA engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Company profile

Filippo Petti
Fiscal year end
Former names

CYAD stock data



24 Mar 21
28 Oct 21
31 Dec 21
Quarter (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

1.8% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 7 6 +16.7%
Opened positions 2 5 -60.0%
Closed positions 1 0 NEW
Increased positions 1 0 NEW
Reduced positions 2 1 +100.0%
13F shares
Current Prev Q Change
Total value 1.49M 5.46M -72.7%
Total shares 283.84K 781.86K -63.7%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Endurant Capital Management 160.69K $845K NEW
Victory Capital Management 79.9K $419K -89.3%
MS Morgan Stanley 24.52K $129K +3.8%
Old Mission Capital 11.32K $60K NEW
WFC Wells Fargo & Co. 6.34K $34K 0.0%
UBS UBS Group AG - Registered Shares 1.06K $6K -44.1%
Pacitti 4 $0 0.0%
Proequities 0 $0
Largest transactions
Shares Bought/sold Change
Victory Capital Management 79.9K -670.01K -89.3%
Endurant Capital Management 160.69K +160.69K NEW
Old Mission Capital 11.32K +11.32K NEW
MS Morgan Stanley 24.52K +900 +3.8%
UBS UBS Group AG - Registered Shares 1.06K -835 -44.1%
BMO Bank of Montreal 0 -87 EXIT
WFC Wells Fargo & Co. 6.34K 0 0.0%
Proequities 0 0
Pacitti 4 0 0.0%

Financial report summary

Content analysis
H.S. sophomore Avg
New words: AA, abnormal, actor, Adicet, Affimed, AgreementSM, Ahead, aid, aka, alleviated, alloreactivity, AlloVir, ambition, AnaptysBio, anti, array, Assoc, ATM, azacitidine, backbone, background, ban, Basel, baseline, Bedrijfsrevisoren, benchmark, benchmarking, bespoke, Beta, biomarker, Black, blunt, Brexit, Britain, calcium, CH, chairmanship, Chamber, checkpoint, clawback, clear, CMC, colon, commandeered, Commerce, compassionate, concomitantly, convey, crucial, customarily, cytochrome, decitabine, deep, depth, devaluation, diverge, diversified, Dominic, doubt, downregulate, downregulation, drew, durable, dynamic, economy, electorate, element, Elmer, emphasized, Eshhar, Eurocell, explanatory, exploded, exploding, extracellular, EY, Feb, Fellow, fifty, fill, fine, firmly, Firstly, foot, Fortune, fragmenting, freedom, freely, frozen, futility, Gastrointestinal, genome, GlaxoSMith, globe, GmbH, gold, Great, Hague, haplotype, HLA, Hofstra, ICFR, ill, immunicy, immunomodulatory, Immunopharma, immunostimulatory, immunosuppressive, induction, insignificantly, invisible, Irish, irradiated, Juno, jurisprudence, Jurkat, KEYTRUDA, kidney, Kim, Kline, KNL, KPMG, Kuur, leaving, leeway, legacy, leukocyte, leveraging, Lincoln, Lisbon, lodging, LPC, manipulation, Marina, marker, maximize, McKinsey, Medigene, Medivation, Mel, MHRA, microsatellite, mitogenic, MMRF, modular, monthly, mOS, mRNA, MSD, MSS, multiplex, multiplexed, multiplexing, naamloze, nascent, Northern, Nouscom, NSG, obliterating, onboard, ORIC, page, pair, Park, Parkinson, passion, Paterson, pembrolizumab, PerkinElmer, pertaining, phosphoinositide, pioneer, pioneering, Piscitelli, plasma, plug, pMMR, pragmatism, premise, prepaid, Prof, proficient, Programme, Promega, proteosome, pursuit, quickly, rebranded, rebranding, rectum, reintroduced, Repare, repertoire, resist, robust, roughly, Sana, SCC, seamlessly, setback, seventeen, Shield, silence, silent, slight, SMART, SME, SQZ, staggered, steadily, stored, striking, strongly, Symposium, Tarceva, technique, thereon, thirty, TME, tradename, transduction, transferrable, transposition, truncated, truncation, Ts, tuning, Udier, underpin, undetected, unqualified, unresponsive, vacant, Versant, vigorously, Viracta, wake, wave, Webinar, white, worsen, XTANDI, Yale, Zelig, zone
Removed: accelerator, activate, activated, adaptor, ade, anaamloze, andPromega, apro, asAssociation, ASH, attainment, attest, Avenue, banked, Beauty, billion, bioactivity, bladder, breast, Bryan, cardio, ceasing, charity, Christian, collaborator, collecting, consulted, contrasted, correction, costimulatory, CRC, cri, crossed, cytotoxic, DAP, deadliest, destroy, destroyed, detection, died, diseased, divesting, domain, elimination, emerged, emerging, encode, England, enrolment, escalation, evade, exceeded, extrapolation, FileNo, filer, fluctuated, formation, fueled, gamma, Garnier, gastric, gathered, Genentech, Gleevec, golden, graft, grafted, Herceptin, hired, Homsy, HSCT, immunized, impressive, inAssoc, includinginter, incomplete, induced, infected, infinite, inflammation, Inhibiting, injecting, intracellular, inventor, irrevocably, isolate, Japanese, Johnson, Jumpstart, kill, killing, Korea, Laguna, leader, LSS, lung, lymphoblastic, malfunctioning, mediated, Michigan, micro, minimal, modulate, monotherapy, mouse, multinational, native, naturally, NDA, neoadjuvant, nonbinding, ovarian, overcoming, Oxley, pancreatic, parachute, paradigm, perspective, PhD, Poor, proceeded, proliferate, rating, regorafinib, relied, rented, resection, resignation, satellite, seasonality, secretion, SEER, Sentman, SHRINK, stimulatory, stressed, sublicensed, sublicensing, successive, suppressing, suppressive, surgical, surviving, Taiwan, thrive, tightly, till, ULBP, undergone, unrelated, vast, version, viability, volatile, window, withdrew, wound, yielded, Zeta


No filings


Method and Apparatus for Automated Independent Parallel Batch-processing of Cells
16 Sep 21
A cell processing device is provided that is suitable for performing independent concurrent processing of a plurality of cell preparations, the cell processing device comprising: (I) a cell processing station; and (II) a plurality of cell processing modules, wherein the plurality of cell processing modules engage and communicate with the cell processing station; wherein each of the plurality of cell processing modules comprises discrete processing compartments defined within, the processing compartments comprising: (i) a reagent pack, the reagent pack comprising one or more reagent vessels; d (ii) one or more fluidic cartridges, each fluidic cartridge comprising one or more cell processing compartments and a cell incubation compartment, wherein each of the processing compartments is in fluid communication with each other.
Compositions and Methods for Improving Persistence of Cells for Adoptive Transfer
10 Jun 21
The present application relates to the field of immunotherapy, more particularly to the manufacture of cells for adoptive cell therapy.
Pooling Signaling and Costimulatory Domains In Flexible Car Design
11 Mar 21
The present application relates to the field of immunotherapy, more particularly to the field of chimeric antigen receptors (CARs).
Steering control mechanism for catheter
16 Nov 20
This document relates to catheter-based therapeutic apparatus and methods for directing therapy within the body of a subject.
Injection catheter for delivering a therapeutic agent into a substrate
20 Apr 20
The invention relates to an injection catheter for delivering a therapeutic agent into a substrate, comprising one or more lumens and a curved delivery element, said lumen serving as a guide for said curved delivery element outside of the substrate; said curved delivery element comprising openings on its distal tip, said distal tip comprising a distal zone and a proximal zone, said injection catheter being characterized in that the specific surface in said distal zone of said distal tip of said curved delivery element is higher than the specific surface in said proximal zone of said distal tip of said curved delivery element.